March 23, 2011
While about 250,000 Australians have hepatitis C virus, just 5 percent choose to initiate therapy. Standard interferon and ribavirin treatment creates a sustained virologic response in up to 50 percent of patients with HCV genotype 1. Many choose a conservative approach due to the side effects of standard therapy, which can include depression, insomnia, muscle pain, and psychotic episodes.
The Alfred Hospital in Melbourne recently was one of six hospitals in Australia and New Zealand to trial an experimental HCV treatment combination that did not include interferon. The all-oral treatment combined the nucleoside polymerase inhibitor RG7128 with danoprevir, an NS3/4A protease inhibitor. The trial, funded by drugmaker Roche, randomly assigned 88 chronic HCV patients to the combination treatment or placebo.
Results of the dose-escalation trial showed the promise of more effective treatment, with some patients clearing the virus within two weeks.
"Introducing this treatment as standard practice is a few years off, but this study provides a proof-of-concept that it can be effective," Roberts said. "Treatment, when successful, can not only arrest the progression of the disease but often it will reduce in severity as the liver remodels itself."
The study, "Oral Combination Therapy with a Nucleoside Polymerase Inhibitor (RG7128) and Danoprevir for Chronic Hepatitis C Genotype 1 Infection (INFORM-1): A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Trial," was published in the Lancet (2010;376(9751):1467-1475).
The Age (Melbourne)
03.15.2011; Kate Hagan
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|
|DACA, Immigrant Rights and the 'Larger Compassion' of the HIV Community|
|Federal Leaders Work Together to Get the Word Out About Research Showing Viral Suppression Prevents HIV Transmission|
|Up Close and Personal at USCA: A Day of Action|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|
|Guidance for Providers Treating HIV-Positive People Displaced by Disasters|